Skip to main content
Sandoz rituximab biosimilar(SDZ-RTX; Rixathon) compared with reference rituximab (Ref-RTX) and shown to have same efficacy outcomes (DAS28 Remission, ACR20/50/70, CDAi/SDAI, HAQ), B cell depletion levels, adverse events & low level antidrug Abs https://t.co/0XWQs23Xcv
Dr. John Cush
Jul-31-2020
×